Table 7 Comparison of anti-VEGF therapy and morphological changes between patients with and without recurrence
Eyes | Anti-VEGF therapy | Morphological changes | |||||||
|---|---|---|---|---|---|---|---|---|---|
bevacizumab | ranibizumab | Patients with morphological improvement | Patients without morphological improvement | ||||||
Eyes | n | Eyes | n | Eyes | n | Eyes | n | ||
Patients with recurrence | 6 | 3 | 50.0% | 3 | 50.0% | 1 | 16.7% | 5 | 83.3% |
Patients without recurrence | 21 | 5 | 23.8% | 16 | 76.2% | 7 | 33.3% | 14 | 66.6% |
χ2 | 1.535 | 0.622 | |||||||
P | 0.319 | 0.633 | |||||||